Khong and Overwijk Journal for ImmunoTherapy of Cancer (2016) 4:56 DOI 10.1186/s40425-016-0160-y REVIEW Adjuvants for peptide-based cancer vaccines Hiep Khong1,2 and Willem W. Overwijk1,2* Open Access Abstract
An amphiphilic dendrimer as a light-activable immunological adjuvant for in situ cancer vaccination Immunological adjuvants are a crucial component of cancer vaccines. Here the authors design a light-activable immunological adjuvant, based on hypoxia-responsive amphiphilic dendrimer nanoparticles loaded with...
Molecular identification of human tumor antigens found to be immunogenic in humans after natural exposure or treatment with cancer vaccines has resulted in a wide array of increasingly focused vaccines. However, as vaccines against cancers (and infectious diseases) have employed increasingly focused and...
Adjuvants are indispensable components of vaccines. Despite being widely used in vaccines, their action mechanisms are not yet clear. With a greater understanding of the mechanisms by which the innate immune response controls the antigen-specific respons
AS15 MPL, QS-21 and CpG 7909 NLRP3 inflammasome MAGE-A3 Cancer Immunotherapeutics: melanoma and non-small-cell lung cancer vaccines [14] ISA 51 mineral oil, surfactant from the mannide monooleate family IFN-γ, Fas ligand peptide vaccine gp100 in a Phase III trial for Melanoma peptide vacci...
Additionally, the mannose modification of PLGA nanoparticles also improves antigen (HPV16 E7 peptide) delivery and induces a robust cellular immunity [Citation158]. Hence, mannose nanoparticles, serving as versatile vaccine delivery systems, have the potential in both the treatment of infectious diseases...
The overall approach was found to be safe in study subjects when the photosensitizer dose was below certain threshold although the potency of poly(I:C)-based adjuvant to enhance HPV peptide vaccination was not studied (Otterhaug et al., 2020). The above studies indicated good safety of poly(...
Dendritic cells (DCs) have the potential for cancer immunotherapy due to their ability to process and present antigens to T-cells and also in stimulating immune responses. However, DC-based vaccines have only exhibited minimal effectiveness against established tumours in mice and humans. The use of...
Several clinical trials suggested that one promising immunotherapeutic approach is cancer vaccines, containing novel adjuvants capable of stimulating innate immunity to result in breakage of immunotolerance in the tumor microenvironment and development of potent antitumor immune responses. In particular, agonis...
Koh YT, Higgins SA, Weber JS, Kast WM (2006) Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund’s adjuvant. J Transl Med 4:42. https://doi.org/10.1186/1479-5876-4-42 Article PubMed PubMed Central Google...